An interventional study of ELITONE UUI in Urge Incontinence, sponsored by Elidah, Inc.. Completed at 1 site in United States. Open to female participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-30.
Sponsored by Elidah, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 135 studies in Urinary Incontinence, Urge with a site in United States — 19 open to participants now, 26 under way, none of them phase 3. Urinary Incontinence, Urge · United States.
Among the 135 studies in Urinary Incontinence, Urge with a site in United States, this one is the 58th largest by enrollment of the 119 interventional ones that give a count, is one of 10 that started in 2020, is one of 72 with no phase, and was the 96th registered.
243 studies on the registry are indexed under Urinary Incontinence, Urge; 39 are open to participants now.
Browse Urinary Incontinence, Urge studies →19 of the 135 studies in Urinary Incontinence, Urge with a site in United States are open now. Recruiting first, the newest first:
Loma Linda University · Sites in United States
Ages 18–89
Axonics, Inc. · Sites in United States, Australia
Ages 18+
Neuspera Medical, Inc. · Sites in United States
Ages 22+
MedtronicNeuro · Sites in United States
Ages 18+
InMode MD Ltd. · Sites in United States
Ages 22–80 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Urinary Incontinence, Urge studies recruiting now, 18 (72%) set no upper age limit and 2 (8%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 21 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
135 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 14 · Phase 4 19
First in 2003; this study’s year is marked. 10 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 82 is close to the median of 86 across 191 interventional studies indexed under Urinary Incontinence, Urge.
Median enrollment 75 across the 119 interventional studies, 47 across the 15 observational. Of the 97 that completed or were terminated, 51 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 135 have an industry lead sponsor. The 10 most frequent:
Elidah, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Elidah, Inc. has 1 study filed under Urinary Incontinence, Urge — fewer than ten, so there is no comparison to draw.
11 of the studies in Urinary Incontinence, Urge with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06797245Medstar Health Research InstituteAPPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women | 2026-11 |
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT07335484Axonics, Inc.Aquarius Pilot Study to Evaluate the New Axonics Trial System | 2026-11 |
| NCT07247136Neuspera Medical, Inc.Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System | 2026-11 |
| NCT06186765Axonics, Inc.F15 Recharge Free Axonics SNM System Clinical Study | 2026-12 |
Add all 11 to your calendar (.ics) → With an account.
Among the 135 studies in Urinary Incontinence, Urge with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to evaluate the effectiveness of the ELITONE-UUI electrical muscle stimulation device on treating urge incontinence. The aim of the device is to stimulate the pelvic floor muscles and surrounding structures to improve urinary incontinence.
The purpose of this research is to evaluate the effectiveness of the ELITONE-UUI electrical muscle stimulation device on treating urge incontinence in women. The aim of the device is to stimulate the pelvic floor muscles and surrounding structures to improve urinary incontinence. This is a randomized prospective controlled study of two active groups with a stimulation frequency difference between the groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Predominant urge urinary incontinence as determined by responses to a series of three standard questions from the King's Health Questionnaire; specifically:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region, with stimulation group A.
Device: ELITONE UUI
Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region with stimulation group B.
Device: ELITONE UUI
External electrical stimulation
Also known as: ELITONE muscle stimulator
Change in Average Number of Urinary Incontinence Episodes Per Day
The efficacy of a treatment for urinary incontinence measures how much the treatment changed urinary incontinence leakage from the beginning to the end of the 6 week period.
Time frame: 6 weeks
Safety Assessed by Number of Serious Adverse Events
Any serious adverse events recorded during the trial.
Time frame: 6 weeks
Efficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL)
The efficacy assessed by change in Incontinence quality of life questionnaire (I-QOL). The scale is as follows: 1 = not at all , 2 = a little, 3 = moderately, 4 = quite a bit and 5 = extremely. The lower the value the less times it happens and the better outcome. A larger results indicate a higher change in I-QOL from beginning to end of trial. The minimum score total is 22 and maximum total score is 110.
Time frame: 6 weeks
Efficacy Assessed by Reduction in Average Pads Used Per Day
Efficacy Assessed by Reduction in Average Pads used per day over the 6 week period.
Time frame: 6 weeks
Efficacy Assessed by Reduction in Average Bathroom Visits
The efficacy assessed by average bathroom visits during the day and night.
Time frame: 6 weeks
| Milestone | Active Group A | Active Group B |
|---|---|---|
| Started | 26 | 56 |
| Completed | 17 | 34 |
| Not completed | 9 | 22 |
The efficacy of a treatment for urinary incontinence measures how much the treatment changed urinary incontinence leakage from the beginning to the end of the 6 week period.
| percentage change | Active Group A | Active Group B |
|---|---|---|
| Change in Average Number of Urinary Incontinence Episodes Per Day | 69.6 ± 30.9 | 66.1 ± 28.7 |
Any serious adverse events recorded during the trial.
| serious adverse events | Active Group A | Active Group B |
|---|---|---|
| Safety Assessed by Number of Serious Adverse Events | 0 ± 0 | 0 ± 0 |
The efficacy assessed by change in Incontinence quality of life questionnaire (I-QOL). The scale is as follows: 1 = not at all , 2 = a little, 3 = moderately, 4 = quite a bit and 5 = extremely. The lower the value the less times it happens and the better outcome. A larger results indicate a higher change in I-QOL from beginning to end of trial. The minimum score total is 22 and maximum total score is 110.
| change of score on a scale | Active Group A | Active Group B |
|---|---|---|
| Efficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL) | -26.6 ± 20.2 | -21.8 ± 15.9 |
Efficacy Assessed by Reduction in Average Pads used per day over the 6 week period.
| percentage of change | Active Group A | Active Group B |
|---|---|---|
| Efficacy Assessed by Reduction in Average Pads Used Per Day | 27.8 ± 57.4 | 36.4 ± 33.5 |
The efficacy assessed by average bathroom visits during the day and night.
| percentage of change | Active Group A | Active Group B |
|---|---|---|
| Efficacy Assessed by Reduction in Average Bathroom Visits | 5.9 ± 29.5 | 0.5 ± 26.0 |
Collected over 6 weeks of study. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Group A | 0/17 (0%) | 0/17 (0%) | 0/17 (0%) |
| Active Group B | 0/34 (0%) | 0/34 (0%) | 0/34 (0%) |
| Age, Categorical(Participants) | Active Group A | Active Group B | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 13 | 23 | 36 |
| >=65 years | 4 | 11 | 15 |
| Age, Continuous(years) | Active Group A | Active Group B | Total |
|---|---|---|---|
| Mean | 53.0 ± 13.8 | 57.8 ± 12.7 | 56.2 ± 13.1 |
| Sex: Female, Male(Participants) | Active Group A | Active Group B | Total |
|---|---|---|---|
| Female | 17 | 34 | 51 |
| Male | 0 | 0 | 0 |
| Race and Ethnicity Not Collected(Participants) | Active Group A | Active Group B | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Active Group A | Active Group B | Total |
|---|---|---|---|
| United States | 17 | 34 | 51 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in May 2021, 6 months.
Results were first posted in Dec 2024, 3 years 7 months after primary completion.
Of 77 interventional studies with no phase under Urinary Incontinence, Urge, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Elidah, Inc.